Disclaimer

Are mesenchymal stem cells or mononuclear cells effective in the treatment of ischemic cardiomyopathy? 🤔 Both cells from the bone marrow origin showed similar improvements in this study. However, MSCs was the only group to project a rise in the 6-minute walk distance and regional myocardial function as peak Eulerian circumferential strain at the site of injection.  

Allogeneic vs Autologous!💥 Does the origin of mesenchymal stem cells (MSCs) affect the results of treatment for ischemic cardiomyopathy? Today's shared study demonstrates that both types of cells exhibit similar regenerative properties, even the administration of allogeneic MSCs did not trigger any donor-specific immune reactions. In terms of dosage, it's noteworthy that 20 million cells show a higher therapeutic effect compared to interventions involving much higher doses.

This study showed that repeated intracoronary administration of bone marrow-derived stem cells with patients with ischaemic heart failure had significantly increased the patients’ exercising capacity. As for the symptoms, there is a stable improvement which was evaluated using the NYHA functional class and Canadian Heart Association Classification of Angina (CCS). 

Let's take a look at this attached clinical summary which highlighted the promising of Intramyocardial Grafting Collagen Scaffold With Mesenchymal Stromal Cells in Patients With Chronic Ischemic Heart Disease! In this paper, the patients experienced improved cardiac function, viable cardiac tissue size, and the scar size remained stable in the combined intervention, which was not the case for those who only received the collagen grafting.